Dr. Gandara on the Utility of TMB in NSCLC
David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.
David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.
Jharna M. Patel, MD, discusses the utility of ChatGPT in genetic counseling for patients with gynecologic cancers.
Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.
The FDA has granted priority review to dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.
The PRECEDE study demonstrated the feasibility of a large-scale early detection and prevention program for pancreatic cancer.
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
In acute myeloid leukemia, investigators are exploring novel agents engineered to target adhesion factors, which can mobilize persistent leukemic stem cells from the bone marrow…
Oncologists present the clinical scenario of a 65-year-old woman with recurrent HR-positive, HER2-low breast cancer, and discuss optimal sequencing of systemic therapies in this setting.